03/22/21 4:00 PMNYSE : RHHBY, ROG, ROGenentech Provides Update on Tominersen Program in Manifest Huntington's DiseaseGenentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today the decision to discontinue dosing in the Phase III GENERATION HD1 study of tominersen in manifest Huntington's disease (HD). The decision was based on the results of a pre-planned review of the data from the PhaseRHEA-AIneutral
03/22/21 2:00 AMNYSE : RO, ROG, RHHBYPivotal Phase III Study Shows Genentech's Tecentriq Helped People With Early Lung Cancer Live Longer Without Their Disease ReturningGenentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the Phase III IMpower010 study evaluating Tecentriq (R) (atezolizumab), compared with best supportive care (BSC), met its primary endpoint of disease-free survival (DFS) at the interim analysis. Tecentriq showedRHEA-AIneutral
03/16/21 2:00 AMNYSE : RO, ROG, RHHBYNew 2-Year Data Show Genentech's Evrysdi (risdiplam) Continues to Demonstrate Improvement or Maintenance of Motor Function in People Aged 2-25 With Type 2 or Type 3 Spinal Muscular Atrophy (SMA)Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced new exploratory 2-year longer-term data from Part 2 of SUNFISH, a global placebo-controlled study evaluating Evrysdi(TM) (risdiplam) in people aged 2-25 years with Type 2 or non-ambulant Type 3 spinal muscular atrophyRHEA-AIneutral
03/11/21 1:00 AMNYSE : RO, ROG, RHHBYGenentech Provides Update on the Phase III REMDACTA Trial of Actemra Plus Veklury in Patients With Severe COVID-19 PneumoniaGenentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the global Phase III randomized, double-blind, multicenter REMDACTA study of Actemra (R) (tocilizumab) plus Veklury (R) (remdesivir), versus placebo plus Veklury, did not meet its primary endpoint. This wasRHEA-AIneutral
03/08/21 1:00 AMNYSE : RO, ROG, RHHBYGenentech Provides Update on Tecentriq U.S. Indication in Prior-Platinum Treated Metastatic Bladder CancerGenentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the company is voluntarily withdrawing the U.S. indication for Tecentriq (R) (atezolizumab) in prior-platinum treated metastatic urothelial carcinoma (mUC, bladder cancer). This decision was made in consultationRHEA-AIvery positive
03/04/21 5:42 PMNYSE : RO, ROG, RHHBYGenentech's Actemra Becomes the First Biologic Therapy Approved by the FDA for Slowing the Rate of Decline in Pulmonary Function in Adults With Systemic Sclerosis-Associated Interstitial Lung Disease, a Rare, Debilitating ConditionGenentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) approved Actemra (R) (tocilizumab) subcutaneous injection for slowing the rate of decline in pulmonary function in adult patients with systemic sclerosis-associatedRHEA-AIneutral
02/24/21 5:00 PMNYSE : RHHBY, RO, ROGGenentech Announces Results From Evrysdi (risdiplam) Study in Infants With Type 1 Spinal Muscular Atrophy (SMA) Published in New England Journal of Medicine Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that Evrysdi(TM) (risdiplam) data from the dose finding Part 1 of the pivotal FIREFISH study in infants with symptomatic Type 1 spinal muscular atrophy (SMA) were published in the February 24, 2021 online issue of theRHEA-AIneutral
02/12/21 1:00 AMNYSE : RO, ROG, RHHBYNew Phase III Data Show Genentech's Faricimab Is the First Investigational Injectable Eye Medicine to Extend Time Between Treatments up to Four Months in Two Leading Causes of Vision Loss, Potentially Reducing Treatment Burden for PatientsGenentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) today announced detailed results from four Phase III studies of its investigational bispecific antibody, faricimab, for the treatment of diabetic macular edema (DME) and neovascular or "wet" age-related macular degeneration (nAMD).RHEA-AIvery positive
01/25/21 1:00 AMNYSE : RO, ROG, RHHBYGenentech's Faricimab Meets Primary Endpoint in Two Global Phase III Studies and Shows Potential to Extend Time Between Treatments up to 16 Weeks for People With Neovascular Age-Related Macular DegenerationGenentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) today announced positive topline results from two identically designed global Phase III studies, TENAYA and LUCERNE, evaluating its investigational bispecific antibody, faricimab, in people living with neovascular or "wet"RHEA-AIneutral
01/21/21 1:00 AMNYSE : RO, ROG, RHHBYFDA Grants Priority Review to Genentech's Esbriet (pirfenidone) for Unclassifiable Interstitial Lung DiseaseGenentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental New Drug Application (sNDA) and granted Priority Review for Esbriet (R) (pirfenidone) for the treatment of unclassifiableRHEA-AIvery positive
